<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3504">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04472728</url>
  </required_header>
  <id_info>
    <org_study_id>BIO101-CL05</org_study_id>
    <nct_id>NCT04472728</nct_id>
  </id_info>
  <brief_title>Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients</brief_title>
  <acronym>COVA</acronym>
  <official_title>Adaptive Design Phase 2 to 3, Randomized, Double-blind, to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BIO101 in the Prevention of the Respiratory Deterioration in Hospitalized COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biophytis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biophytis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVA clinical study is a global multicentric, double-blind, placebo-controlled, group&#xD;
      sequential and adaptive 2 parts phase 2-3 study targeting in patients with SARS-CoV-2&#xD;
      pneumonia. Part 1 is a Phase 2 exploratory Proof of Concept (PoC) study to provide&#xD;
      preliminary data on the activity, safety and tolerability of BIO101 in the target population.&#xD;
      Part 2 is a phase 3 pivotal randomized study to provide further evidence of safety and&#xD;
      efficacy of BIO101 after 28 days of double-blind dosing. BIO101 is the investigational new&#xD;
      drug that activates the Mas receptor (MasR) through the protective arm of the Renin&#xD;
      Angiotensin System (RAS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biophytis is developing BIO101, an investigational new drug, an oral preparation of&#xD;
      immediate-release 20-hydroxyecdysone (20E) at ≥ 97% purity. BIO101 activates MasR on the&#xD;
      protective arm of the Renin Angiotensin System (RAS). The engagement of MasR by BIO101 is&#xD;
      responsible for a number of preclinical beneficial activities in normal and pathological&#xD;
      contexts.&#xD;
&#xD;
      The COVA clinical study is a global, multicentric, double-blind, placebo-controlled, group&#xD;
      sequential and adaptive 2 parts phase 2-3 study in participants with SARS-CoV-2 pneumonia.&#xD;
      Part 1 is a Phase 2 exploratory Proof of Concept (PoC) study to provide preliminary data on&#xD;
      the activity, safety and tolerability of BIO101 in the target population. Part 2 is a phase 3&#xD;
      pivotal randomized study to provide further evidence of safety and efficacy of BIO101 after&#xD;
      28 days of dosing.&#xD;
&#xD;
      The trial will use an adaptive design based on pre-specified criteria, using an independent&#xD;
      external Data Monitoring Committee (DMC) to monitor safety, efficacy, and review data at&#xD;
      appropriate intervals to allow the initiation of the confirmatory part of the study.&#xD;
&#xD;
      The general objectives of the study are:&#xD;
&#xD;
        -  The purpose of Part 1 is to obtain preliminary indication of activity of BIO101, in&#xD;
           preventing respiratory deterioration in the target population (50 patients, age ≥ 55&#xD;
           years) and provide preliminary data on the safety and tolerability of BIO101 in the&#xD;
           target population&#xD;
&#xD;
        -  The purpose of Part 2 is to re-assess the sample size that is needed for the&#xD;
           confirmatory part of the study and to provide confirmation on the benefit of BIO101 and&#xD;
           safety in the larger target population (up to 310 patients)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>End-of-Part 1 interim analysis: Proportion of subjects with all cause mortality or with respiratory failure.</measure>
    <time_frame>up to 28 days</time_frame>
    <description>For interim analysis intended to obtain indication of activity of BIO101.&#xD;
Primary endpoint:&#xD;
• Proportion of subjects with negative events, of either of the following:&#xD;
All-cause mortality&#xD;
Respiratory failure, defined as any of the following:&#xD;
Requiring mechanical ventilation (including cases that will not be intubated due to resource restrictions and triage) Requiring ECMO Requiring high-flow oxygen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For part-2 sample size interim analysis: Proportion of subjects with all cause mortality or with respiratory failure.</measure>
    <time_frame>up to 28 days</time_frame>
    <description>For sample size re-assessment for part 2, time frame - up to 28 days:&#xD;
• Proportion of participants with negative events, of either of the following:&#xD;
All-cause mortality&#xD;
Respiratory failure, defined as any of the following:&#xD;
Requiring mechanical ventilation (including cases that will not be intubated due to resource restrictions and triage) Requiring high-flow oxygen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For the final analysis: Proportion of subjects with all cause mortality or respiratory failure.</measure>
    <time_frame>up to 28 days</time_frame>
    <description>• Proportion of participants with of subjects with negative events, of either of the following.&#xD;
All-cause mortality&#xD;
Respiratory failure, defined as any of the following:&#xD;
Mechanical ventilation (including cases that will not be intubated due to resource restrictions and triage) Requiring ECMO Requiring high-flow oxygen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interim analysis; indication of activity of BIO101: Oxygen saturation by pulse oximetry (SpO2) SpO2 / Fraction of inspired oxygen (FiO2) ratio</measure>
    <time_frame>28 days</time_frame>
    <description>• SpO2/FiO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interim analysis; indication of activity of BIO101: Inflammatory markers</measure>
    <time_frame>28 days</time_frame>
    <description>• Inflammatory markers including:&#xD;
IL 6&#xD;
TNFα&#xD;
D-dimer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interim analysis; indication of activity of BIO101: Renin Angiotensin System biomarkers</measure>
    <time_frame>28 days</time_frame>
    <description>• Renin Angiotensin System biomarkers:&#xD;
Angiotensin 2&#xD;
Angiotensin-converting enzyme (ACE) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key secondary endpoint for final analysis: Proportion of participants with positive events</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>• official discharge from hospital care by the department due to improvement in participant condition (self-discharge by participant is not considered a positive event)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional secondary endpoints for final analysis: Respiratory function</measure>
    <time_frame>28 days</time_frame>
    <description>Oxygen saturation in arterial blood, measured by pulse-oximetry (SpO2) SpO2/FiO2 Proportion of participants with CPAP/BiPAP events, defined as requiring CPAP/BiPAP in participants entering the study on low flow oxygen)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional secondary endpoints for final analysis:proportion of patients who experienced negative events</measure>
    <time_frame>28 days</time_frame>
    <description>Time to events, of either of the following:&#xD;
All-cause mortality&#xD;
Respiratory failure, defined as any of the following: Requiring mechanical ventilation (including cases that will not be intubated due to resource restrictions and triage); Requiring ECMO; Requiring high-flow oxygen • Proportion of participants with CPAP/BiPAP events, defined as requiring CPAP/BiPAP in participants entering the study on low flow oxygen)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional secondary endpoint for final analysis: The National Early Warning Score 2 (NewS2):</measure>
    <time_frame>28 days</time_frame>
    <description>National Early Warning Score 2 (NewS2): scores: 0-7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional secondary endpoint for final analysis: Population Pharmacokinetics study (pop-PK)</measure>
    <time_frame>1day</time_frame>
    <description>Cmax: Peak Plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional secondary endpoint : Population Pharmacokinetics study (pop-PK)</measure>
    <time_frame>1 day</time_frame>
    <description>tmax: Time to reach peak plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional secondary endpoint: Population Pharmacokinetics study (pop-PK)</measure>
    <time_frame>1 day</time_frame>
    <description>AUC: Area under the plasma concentration versus time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional secondary endpoint: Proportion of participants with events of all-cause mortality</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Proportion of participants with events of all-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional secondary endpoint: time to event: negative events</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Time to events, of either of the following:&#xD;
All-cause mortality&#xD;
Respiratory failure, defined as any of the following:&#xD;
Requiring mechanical ventilation (including cases that will not be intubated due to resource restrictions and triage)&#xD;
Requiring ECMO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional secondary endpoint: time to event: positive events</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Time to event: official discharge from hospital care due to improvement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Covid-19</condition>
  <condition>SARS-CoV2</condition>
  <arm_group>
    <arm_group_label>BIO101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIO101 350 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIO101</intervention_name>
    <description>BIO101 capsules</description>
    <arm_group_label>BIO101</arm_group_label>
    <other_name>Sarconeos (BIO101)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sarconeos (placebo)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 45 and older (in France: 55 and older)&#xD;
&#xD;
          2. A confirmed diagnosis of COVID-19 infection, within the last 28 days, prior to&#xD;
             randomization, as determined by PCR or other approved commercial or public health&#xD;
             assay, in a specimen as specified by the test used.&#xD;
&#xD;
          3. Hospitalized, in observation or planned to be hospitalized due to COVID-19 infection&#xD;
             symptoms with anticipated hospitalization duration &gt;=3 days&#xD;
&#xD;
          4. With evidence of pneumonia based on all of the following:&#xD;
&#xD;
               1. Clinical findings on a physical examination&#xD;
&#xD;
               2. Respiratory symptoms developed within the past 14 days&#xD;
&#xD;
          5. With evidence of respiratory decompensation that started not more than 7 days before&#xD;
             start of study medication and present at screening, meeting one of the following&#xD;
             criteria, as assessed by healthcare staff:&#xD;
&#xD;
               1. Tachypnea: ≥25 breaths per minute&#xD;
&#xD;
               2. Arterial oxygen saturation ≤92%&#xD;
&#xD;
               3. A special note should be made if there is suspicion of COVID-19- related&#xD;
                  myocarditis or pericarditis, as the presence of these is a stratification&#xD;
                  criterion&#xD;
&#xD;
          6. Without a significant deterioration in liver function tests:&#xD;
&#xD;
               1. ALT and AST ≤ 5x upper limit of normal (ULN)&#xD;
&#xD;
               2. Gamma-glutamyl transferase (GGT) ≤ 5x ULN&#xD;
&#xD;
               3. Total bilirubin ≤ 5×ULN&#xD;
&#xD;
          7. Willing to participate and able to sign an informed consent form (ICF)&#xD;
&#xD;
          8. Female subjects should be:&#xD;
&#xD;
             at least 5 years post-menopausal (i.e., persistent amenorrhea 5 years in the absence&#xD;
             of an alternative medical cause) or surgically sterile; OR&#xD;
&#xD;
               1. Have a negative urine pregnancy test at screening&#xD;
&#xD;
               2. Be willing to use a contraceptive method as outlined in inclusion criterion 9&#xD;
                  from screening to 30 days after last dose.&#xD;
&#xD;
          9. Male subjects who are sexually active with a female partner must agree to the use of&#xD;
             an effective method of birth control throughout the study and until 3 months after the&#xD;
             last administration of investigational product; Note: medically acceptable methods of&#xD;
             contraception that may be used by the subject and/or partner include combined oral&#xD;
             contraceptive, contraceptive vaginal ring, contraceptive injection, intrauterine&#xD;
             device, etonogestrel implant, each supplemented with a condom, as well as&#xD;
             sterilization and vasectomy.&#xD;
&#xD;
         10. Male subjects must agree not to donate sperm for the purpose of reproduction&#xD;
             throughout the study and until 3 months after the last administration of&#xD;
             investigational product;&#xD;
&#xD;
         11. For France only: Being affiliated with a European Social Security.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not needing or not willing to remain in a healthcare facility during the entire study&#xD;
             medication (i.e. while receiving study medication)&#xD;
&#xD;
          2. Moribund condition (death likely in days) or not expected to survive for &gt;7 days - due&#xD;
             to other and non-COVID-19 related conditions&#xD;
&#xD;
          3. Patient on invasive mechanical ventilation via an endotracheal tube, or extracorporeal&#xD;
             membrane oxygenation (ECMO), or high flow Oxygen&#xD;
&#xD;
          4. Patient within 7 days of participating in other therapeutic clinical trial with&#xD;
             angiotensin-converting-enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB)&#xD;
             or recombinant ACE-2&#xD;
&#xD;
          5. Patient not able to take medications by mouth (as capsules or as a powder, mixed in&#xD;
             water).&#xD;
&#xD;
          6. Disallowed concomitant medication:&#xD;
&#xD;
             a. Consumption of any herbal products containing 20-hydroxyecdysone and derived from&#xD;
             Leuzea carthamoides; Cyanotis vaga or Cyanotis arachnoidea is not allowed (e.g.&#xD;
             performance enhancing agents)&#xD;
&#xD;
          7. Any known hypersensitivity to any of the ingredients, or excipients of the study&#xD;
             medication, BIO101&#xD;
&#xD;
          8. In France:&#xD;
&#xD;
               -  Non-affiliation to compulsory French social security scheme (beneficiary or&#xD;
                  right-holder)&#xD;
&#xD;
               -  Being under tutelage or legal guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Capucine Morelot-Panzini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Département R3S GHU APHP-Sorbonne Université, Pitié Salpetrière</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shmuel Agus, MD</last_name>
    <phone>+16176424891</phone>
    <email>sam.agus@biophytis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Waly Dioh, PhD</last_name>
    <phone>+33144272339</phone>
    <email>waly.dioh@biophytis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alpesh Nair, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barnum Medical Research, Inc. 1029 Keyser Ave Suite H</name>
      <address>
        <city>Natchitoches</city>
        <state>Louisiana</state>
        <zip>71457</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otis Barnum, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beaumont Health</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Girish Nair, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Pierre</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DeVit, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Pierre</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane De Wit, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ-Sint Maarten</name>
      <address>
        <city>Mechelen</city>
        <zip>2800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muriel Lins, MD</last_name>
      <phone>+3215892040</phone>
      <email>muriel.lins@Emmaus.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU CLU Namur (Saint-Elisabeth) Place Louise Godin</name>
      <address>
        <city>Namur</city>
        <zip>15 5000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Martinot, MD</last_name>
      <email>martinot.j@respisom.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vera Cruz</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Neuenschwander, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Stadnik, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Municipal de Barueri Dr. Francisco Moran</name>
      <address>
        <city>Barueri</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nara Moraes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital e Maternidade Celso Pierro - PUCCAMP</name>
      <address>
        <city>Campinas</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Patelli Lima, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto</name>
      <address>
        <city>São José Do Rio Preto</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanna Lobo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avenida Dr. Enéas de Carvalho Aguiar, 44 - Centro de Pesquisa Clínica Prof. Dr. Fúlvio Pileggi - Bloco 1 - 1º Andar</name>
      <address>
        <city>São Paulo</city>
        <zip>103.034</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludhmila A Hajjar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unité ambulatoire Service de Pneumologie, Médecine Intensive et Réanimation (SPMIR) 47-83 Boulevard de l'Hôpital</name>
      <address>
        <city>Paris</city>
        <state>Paris Cedex 13</state>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Capucine Morélot-Panzini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Argenteuil</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaetan Plantefeve, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud Desclaux, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Rene Dubos</name>
      <address>
        <city>Cergy-Pontoise</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edouard Devaud, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental de Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Guimard, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière, 47 bd de l'Hôpital, 75013 Paris</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Pourchet, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>FDI Clinical Research - San Juan City Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricardo Fernandez, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 6, 2020</study_first_submitted>
  <study_first_submitted_qc>July 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

